With cutting-edge hospital infrastructure being put in place, government authorities rolling out evermore supportive regulatory upgrades, big pharma championing ‘clinical trial diversity’ with greater non-Caucasian representation in trial cohorts, and a high regional prevalence of genetic diseases, it seems that…
Sovereign wealth funds (SWFs) in the Gulf Cooperation Council (GCC) countries are increasingly investing in healthcare and the life sciences to reinforce their local industries and pursue the region’s economic…
From humble origins, taiba can now count on a unique two decades of experience in bringing innovative rare disease products to patients across the MENA region. The Dubai headquartered company,…
Drawing on a quarter of a century of pharmaceutical industry experience, over 20 years of which has been spent in the UAE, Ayman Mokhtar today heads up Middle East, North…
Maher Abouzeid outlines Medserve’s role as a healthcare projects incubator, focusing on identifying and filling gaps in healthcare services across the Middle East & Africa region. Their hands-on approach includes…
Drawing on two decades of experience within Bayer Consumer Health Middle East, and now as VP and head of the firm’s Middle East/Pakistan Cluster, Mohamed Galal discusses the transformative impact…
As the UAE’s only gastrointestinal oncologist, Professor Humaid Al-Shamsi is well-placed to comment on the evolution of cancer care in the country, noting massive leaps forward in terms of technology,…
A charismatic force at the forefront of the country’s health transformation efforts, Dr Amin Al Amiri currently serves as assistant undersecretary at the UAE Ministry of Health as well as…
Over the past few decades, the UAE has worked hard to attract top global talent to fill the gaps that its small local population was unable to. While the high…
Thanks to favourable regulations from the Ministry of Health and Prevention (MoHaP) which include fast-track regulatory pathways, patients in the UAE are gaining access to innovative medicines in similar time…
As profit margins in established markets decreased, “pharmerging markets” became the new El Dorado for pharma and medtech companies in the 2010s. Many put in big investments only to discover…
Globally, while there is broad stakeholder alignment on topics like clinical trials and innovation, there is real divergence in approaches to pharmacoeconomics and health technology assessment (HTA). This is perhaps…
Long considered a destination of choice for life science multinationals seeking to tap into the latent potential of Middle Eastern markets, the United Arab Emirates’ pharmaceuticals, medtech and healthcare sectors…
See our Cookie Privacy Policy Here
